YOLFTbeta
Mesoblast Ltd

Mesoblast Ltd

MSB · AU · Healthcare / Biotechnology

1.93AUD-0.03 (-1.28%)

Price History

Full chart

Market Stats

Previous Close1.96
Open1.96
Day Range1.93 – 2.00
52-Week Range1.88 – 3.31
Volume2.54M
Market Cap2.65B
P/E (TTM)0.00
Forward P/E454.55
EPS-0.06
Dividend Yield0.00%
Beta0.82
50-Day Avg2.23
200-Day Avg2.26

About

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
  • Employees108
  • Headquarters55 Collins Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://www.mesoblast.com

Leadership

  • Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director · b. 1957
  • Mr. James Michael O'Brien CPA, M.B.A.Chief Financial Officer · b. 1966
  • Dr. Eric A. Rose M.D.Chief Medical Officer & Executive Director · b. 1951
  • Mr. Paul Hughes BPHARMGlobal Head of Corporate Communications & Joint Company Secretary
  • Mr. Anthony WhealHead of Human Resources
  • Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer · b. 1959
  • Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality Management
  • Mr. Daniel Devine B.Sc., J.D., M.B.AHead of Special Projects
  • Mr. Justin Horst B.S.Head of Manufacturing
  • Dr. Fiona See Ph.D.Senior VP & Head of Translational Research

Financials

Income Statement

Currency: USD2005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue502.88K2.82M1.68M909.81K890.71K5.50K120.92M38.28M28.79M25.98M23.75M42.55M2.41M17.34M16.72M32.16M7.46M10.21M7.50M5.90M17.20M122.89M
Growth (%)-+461.11%-40.49%-45.82%-2.10%-99.38%+2198468.82%-68.34%-24.80%-9.75%-8.59%+79.16%-94.33%+618.95%-3.57%+92.30%-76.81%+36.95%-26.54%-21.32%+191.39%+614.56%
Cost of Revenue-------21.64M21.27M25.43M23.78M29.76M12.06M5.51M75.17M81.50M85.73M63.57M54.92M41.07M5.13M19.55M
Gross Profit502.88K2.82M1.68M909.81K890.71K5.50K120.92M38.28M7.52M546.00K-35.00K12.79M-9.65M11.83M-58.45M-49.34M-78.28M-53.36M-47.42M-35.17M12.07M103.34M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%26.12%2.10%-0.15%30.05%-400.21%68.24%-349.55%-153.44%-1049.83%-522.58%-632.20%-595.87%70.17%84.09%
Operating Expense1.49M9.11M8.69M8.85M10.32M10.39M27.16M87.00M67.60M72.92M113.36M68.67M80.39M89.17M21.75M25.53M30.82M27.21M21.87M48.98M74.51M155.74M
Operating Income-986.54K-6.28M-7.01M-7.94M-9.43M-10.39M93.76M-48.72M-60.08M-72.38M-113.39M-55.89M-90.04M-77.34M-80.20M-74.87M-109.10M-80.57M-69.29M-84.15M-62.44M-52.40M
Operating Margin-196.18%-222.70%-417.64%-872.67%-1058.60%-188851.78%77.54%-127.28%-208.71%-278.58%-477.48%-131.35%-3733.08%-445.99%-479.62%-232.84%-1463.20%-789.09%-923.73%-1425.74%-363.08%-42.64%
EBITDA-1.34M-8.14M-6.95M-7.78M-9.31M-10.97M92.44M-48.34M-59.31M-67.01M-90.19M-28.07M-87.16M-74.69M-84.53M-68.97M-84.65M-76.57M-58.55M-56.08M-73.66M-43.62M
EBITDA Margin-267.31%-288.65%-413.95%-855.44%-1045.14%-199515.44%76.44%-126.29%-206.02%-257.92%-379.79%-65.98%-3613.52%-430.71%-505.53%-214.49%-1135.35%-749.91%-780.56%-950.14%-428.30%-35.50%
Net Income-1.47M-8.30M-8.73M-10.06M-12.29M-14.78M90.61M-71.15M-61.66M-80.96M-119.37M-4.13M-76.81M-35.29M-89.80M-77.94M-98.81M-91.35M-81.89M-87.96M-102.14M-58.76M
Net Income Margin-292.39%-294.09%-519.74%-1105.99%-1379.29%-268743.55%74.93%-185.86%-214.21%-311.62%-502.64%-9.70%-3184.70%-203.51%-537.01%-242.38%-1325.25%-894.59%-1091.71%-1490.27%-593.92%-47.82%
R&D491.77K5.36M4.58M6.21M7.15M7.57M15.31M36.94M43.11M55.30M77.59M50.01M58.91M65.93M59.81M56.19M53.01M32.81M27.19M25.35M34.81M99.65M
R&D as % of Total Revenue97.79%189.89%273.01%682.27%802.24%137564.55%12.66%96.49%149.75%212.88%326.73%117.54%2442.54%380.18%357.70%174.74%711.00%321.37%362.47%429.57%202.39%81.09%
Interest Expense107.12K110.09K54200014.91K28904.33M10.53M9.31M01.83M11.33M14.72M10.71M17.29M19.44M20.66M21.75M24.36M
Interest Expense % of Total Revenue21.30%3.90%0.03%0.00%0.00%0.00%0.01%0.00%0.00%16.66%44.34%21.88%0.00%10.55%67.74%45.76%143.70%169.31%259.22%350.02%126.49%19.82%

Balance Sheet

Currency: USD2005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets21.47M16.38M21.24M27.79M26.98M39.51M763.25M720.46M883.71M899.31M1.02B684.02M655.69M692.44M652.12M733.60M744.72M662.14M669.41M669.15M784.68M773.08M
Total Liabilities2.20M4.42M698.90K1.57M1.19M1.60M247.41M241.61M253.45M327.60M408.57M155.86M138.92M146.44M171.06M184.28M163.32M165.10M167.58M188.80M187.24M204.67M
Total Equity19.26M11.97M20.54M26.22M25.79M37.92M515.84M478.85M630.27M571.72M609.36M528.16M516.77M546.01M481.05M549.33M581.40M497.04M501.84M480.36M597.44M568.40M
Cash15.09M7.85M12.06M14.09M16.53M32.05M263.23M206.75M7.88M3.83M27.51M21.86M45.76M37.76M50.43M129.33M136.88M60.03M70.92M62.56M161.16M47.39M
Total Debt-------------59.40M81.29M99.31M105.50M106.91M116.50M118.92M128.16M127.33M
Net Debt-15.09M-7.85M-12.06M-14.09M-16.53M-32.05M-263.23M-206.75M-7.88M-3.83M-27.51M-21.86M-45.76M21.63M30.86M-30.01M-31.39M46.87M45.58M56.36M-33.00M79.94M

Cash Flow

Currency: USD2005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-604.81K-3.18M-9.10M-6.20M-9.24M-9.66M108.23M-72.12M-54.08M-81.86M-121.71M-88.00M-95.47M-75.01M-57.79M-56.37M-106.68M-65.78M-63.27M-48.46M-49.95M-43.83M
Investing Cash Flow-4.97M-4.06M-3.38M-5.35M266.89K-343.45K4.71M5.33M-5.04M-40.81M-5.61M-1.73M142.00K-1.15M-1.00M-3.27M-1.65M-232.00K-194.00K-97.00K120.00K-1.02M
Financing Cash Flow20.67M-16.75M13.60M11.39M25.54M126.09M4.88M169.35M2.43M45.85M62.07M60.01M68.61M71.61M137.04M114.47M-9.87M74.50M40.25M147.34M-15.33M
Capital Expenditure752.61K153.48K181.85K100.96K170.02K87.11K461.55K2.71M2.84M37.92M2.72M922.00K311.00K201.00K279.00K2.25M1.65M232.00K314.00K331.00K730.00K898.00K
Free Cash Flow-1.36M-3.34M-9.28M-6.30M-9.41M-9.74M107.77M-74.82M-56.92M-119.78M-124.42M-88.92M-95.78M-75.21M-58.07M-58.61M-108.33M-66.01M-63.58M-48.79M-50.68M-44.73M
Dividends Paid---------------0000000
FCF to OCF224.44%104.82%102.00%101.63%101.84%100.90%99.57%103.75%105.25%146.32%102.23%101.05%100.33%100.27%100.48%103.98%101.54%100.35%100.50%100.68%101.46%102.05%
Dividend Paid to FCF---------------0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Earnings

Report DateFeb 26, 2014Aug 26, 2014Feb 23, 2015Aug 17, 2015Dec 16, 2015Feb 17, 2016May 9, 2016Aug 24, 2016Nov 14, 2016Feb 26, 2017May 24, 2017Aug 29, 2017Nov 14, 2017Feb 27, 2018May 30, 2018Aug 29, 2018Nov 15, 2018Feb 20, 2019May 30, 2019Aug 29, 2019Nov 25, 2019Feb 26, 2020May 29, 2020Aug 26, 2020Nov 19, 2020Feb 26, 2021Jun 2, 2021Aug 30, 2021Nov 23, 2021Feb 24, 2022May 31, 2022Aug 31, 2022Nov 23, 2022Feb 27, 2023May 25, 2023Aug 30, 2023Nov 22, 2023Feb 28, 2024Apr 30, 2024Aug 28, 2024Nov 20, 2024Feb 26, 2025May 30, 2025Aug 28, 2025Nov 26, 2025May 29, 2026Feb 25, 2027
EPS Estimate-0.120.04-0.21-0.22--0.14-0.14-0.15-0.16-0.14-0.11-0.08-0.13-0.11-0.10-0.13-0.11-0.11-0.07-0.14-0.13-0.15-0.12-0.11-0.17-0.07-0.18-0.03-0.14-0.14-0.03-0.03-0.03-0.04-0.17-0.07-0.03-0.02-0.02-0.03-0.01-0.02-0.01-0.04-0.01-0.01-
EPS Actual0.000.000.000.00-0.05-0.09-0.120.19-0.03-0.14-0.07-0.16-0.04-0.05-0.12-0.17-0.11-0.14-0.14-0.12-0.03-0.14-0.09-0.17-0.19-0.12-0.11-0.03-0.10-0.12-0.03-0.03-0.02-0.10-0.08-0.09-0.03-0.020.000.00-0.01-0.040.00-0.04-0.010.00-
Surprise100.00%-100.00%100.00%100.00%-38.21%14.29%226.67%81.25%0.00%36.36%-100.00%69.23%54.55%-20.00%-30.77%0.00%-27.27%-100.00%14.29%76.92%6.67%25.00%-54.55%-11.76%-71.43%38.89%-6.67%28.57%14.29%-9.33%-13.33%19.00%-150.00%52.94%-28.57%12.33%-22.50%100.00%100.00%-40.00%-100.00%100.00%0.00%30.00%100.00%-
Timing------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hours-After-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours--After-hours----Pre-market---

Key Statistics & Ratios

Market Cap2.65B
Enterprise Value2.96B
Trailing P/E0.00
Forward P/E454.55
PEG Ratio0.13
Price / Sales22.03
Price / Book3.56
EPS-0.06
Book Value0.6226
Revenue (TTM)120.25M
Gross Profit (TTM)96.22M
EBITDA-44.60M
Profit Margin-47.82%
Operating Margin-33.28%
Return on Equity-9.86%
Return on Assets-4.11%
Shares Outstanding1.30B
Shares Float861.10M
Beta0.82
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
17.45%
Insiders
36.28%
Retail / Other
46.27%

Top Fund Holders

  • Vanguard International Stock Index-Total Intl Stock Indx
    7.33M1.13%
  • Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund
    3.16M0.49%
  • iShares Core MSCI EAFE ETF
    2.19M0.34%
  • iShares MSCI EAFE Small Cap ETF
    2.14M0.33%
  • DFA Asia Pacific Small Company Series
    1.56M0.24%
  • Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index
    1.28M0.20%
  • iShares Core MSCI Total International Stock ETF
    742.48K0.11%
  • Schwab Strategic Tr-Schwab International Small Cap Equity ETF
    701.02K0.11%
  • College Retirement Equities Fund-Stock Account
    473.07K0.07%
  • Vanguard International Stock Index-Pacific Stock Index
    457.92K0.07%

Stock Splits

  • Dec 5, 2023135:128
  • Aug 29, 2017299:296